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Radiotherapya b s t r a c t
Background: Early-stage oropharyngeal squamous cell carcinoma (OPSCC) can currently be treated by
surgical resection or definitive radiotherapy (RT). The aim of this study is to review the outcomes of
early-stage OPSCC submitted to surgery or primary RT. Preliminary results have shown similar overall
survival (OS) and locoregional recurrence-free survival (LRFS).
Material/Methods: Retrospective study of patients with cT1-T2 cN0-N1 OPSCC, diagnosed between
January 2009 and December 2014, treated with surgery or primary RT.
Results: 61 patients with cT1-T2 cN0-N1 OPSCC were included. Forty-two (69%) were submitted to sur-
gical resection, of which 37 (88%) had adjuvant treatment (24 received RT and 13 chemoradiotherapy).
Nineteen (31%) were treated with primary RT, and 3 of them had concurrent chemotherapy. RT was given
with intensity-modulated radiation therapy (IMRT) (71%) or three-dimensional conformal radiation ther-
apy (3D-CRT) (29%). At a median follow-up of 5.4 years, there were 3 tumor persistences, 5 local failures,
2 regional failures and no distant metastasis. The 3-year and 5-year OS were 77% and 71% in the RT group
vs. 71% and 59% in the surgery group, respectively (HR 0.60, 95% CI 0.22–1.61; p = 0.30). The 3-year and 5-
year LRFS were 71% and 64% in the RT group vs. 66% and 50% in the surgery group, respectively (HR 0.59,
95% CI 0.24–1.45; p = 0.24). Up to 34% had acute grade 3 toxicity and 11% had grade 4 osteoradionecrosis
of the jaw.
Conclusions: Longer follow-up still does not show a significant difference in OS and LRFS between both
treatments. Because most patients submitted to surgery required adjuvant RT and since its side-effects
were not negligible, further studies are warranted to better suit the first treatment for each patient
and to prevent the need for adjuvant treatment and the risk of toxicity.
 2018 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and
Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Introduction
Oropharyngeal squamous cell carcinoma (OPSCC) is a relatively
rare disease. In the United States, each year, there is approximately
49,670 new cases, which represents about 2.9% of all new cancer
cases, and about 9,700 deaths [1]. Tobacco and alcohol are two of
the main risk factors, affecting older patients who also have highrisk of second head and neck or aerodigestive cancer due to field
cancerization [2]. While prevention campaigns against smoking
have led to a decrease in these tumors [3], there has been a signif-
icant increase in OPSCC related to human papillomavirus (HPV),
which currently represents approximately 39% of OPSCC in Europe
and 56% in North America [4]. It presents mostly in younger
patients without smoking or alcohol habits [3] and is associated
with improved local control rate, progression-free survival and
overall survival [5,6].
The management of patients with OPSCC remains controversial.
In the past, it was usually treated with open surgery, which was
associated with severe complications, poor function, bad cosmetic
results and did not avoid adjuvant therapy in many cases. Then
attention was turned to organ preservation approaches with radio-
therapy (RT) as primary treatment [6].
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National Comprehensive Cancer Network (NCCN 2.2017), recom-
mend definite RT, primary surgery or, in case of T2N1, chemoradio-
therapy (CRT). After RT, persistent or progressive disease can be
treated with resection of residual primary or neck dissection.
And after primary surgery, if there is extracapsular spread or a pos-
itive margin (high-risk features), the patient should receive adju-
vant CRT. When other adverse features are present (pT3-4
primary, N2-3 nodal disease, nodal disease in levels IV or V, per-
ineural invasion or vascular embolism), adjuvant RT should be
given and concomitant systemic therapy can also be considered.
Even though surgery and primary RT seem to be equally effec-
tive in terms of local control and overall survival [7,8], no random-
ized trial comparing both options in early-stage OPSCC has been
published yet and most data come from retrospective trials. Two
randomized controlled trials are currently ongoing (EORTC 1420
and ORATOR), but early results are expected in 2021 [9].
The purpose of this study is to present a retrospective, nonran-
domized analysis of the outcomes of OPSCC submitted to primary
surgery or primary RT in a single tertiary center.Material and methods
Patients
Retrospective study with the following inclusion criteria: (1)
patients diagnosed with histologically confirmed OPSCC between
January 2009 and December 2014; (2) clinical stage T1 or T2 N0/
N1 M0; (3) primary treatment with surgery or RT.Evaluation
All patients were initially evaluated by a multidisciplinary
tumor board. Diagnosis was established by biopsy. The extent of
the disease was evaluated with a detailed physical examination
of the head and neck region, flexible fiberoptic endoscopic exami-
nation, computed tomography or magnetic resonance imaging of
head and neck region with contrast enhancement, chest X-ray,
complete blood counts, liver function tests and basic metabolic
panel. Dental evaluation and preventive measures or necessary
tooth extractions were performed before any treatment. The dis-
ease was staged according to the 7th edition of Tumor Node Metas-
tasis (TNM) system of American Joint Committee on Cancer (AJCC,
2010).Treatment
Patients were submitted either to primary surgery or primary
RT. Resectable tumors were selected to surgery at the description
of the treating physician. When clinically indicated, according to
NCCN guidelines, adjuvant RT was delivered. If one high risk factor
or more than one adverse feature were present, RT was given con-
comitantly with chemotherapy (CT). Tumors where surgery would
have been too mutilating, were treated with primary RT. Patients
with nodal disease also received concomitant CT, unless they had
more than 70 years-old or co-morbidities that increased the risk
of toxicity.
Surgical approach was chosen according to the location of the
primary tumor (partial pharyngectomy, partial tonsillectomy,
hemiglossectomy) and always included unilateral or bilateral
lymph node dissection.
RT was administered as intensity-modulated radiation therapy
(IMRT) using simultaneous integrated boost (SIB) or three-
dimensional conformal radiation therapy (3D-CRT). The prescribeddose was 66–70 Gy to the high-risk planning target volume (PTV)
and 50–54 Gy to the low/intermediate-risk PTV.
High-dose cisplatin was used as systemic therapy (intravenous
administration of 100 mg/m2 at D1, D22, D43).
We analyzed patient charts, multidisciplinary clinical evalua-
tion, imaging and clinical data regarding the tumor, primary and
adjuvant therapies, treatment-related morbidity and tumor
response.
Acute toxicity (any adverse event occurring within 90 days of
RT), was graded according to Common Terminology Criteria for
Adverse Events (v4.0). Late toxicity was scored according to Radi-
ation Therapy Oncology Group/European Organization for
Research and Treatment of Cancer criteria.Follow-up
Patients were typically evaluated 1–2 months after the end of
treatment and then every 3 months during 3 years, every 6 months
during the following 2 years and then annually. Post-treatment
baseline imaging of the head and neck region was carried out
within 2 months of treatment and then every 6 months. Chest X-
ray and laboratory evaluation were performed every 6 months. A
positron emission tomography was also obtained when clinically
indicated. Any suspicious lesion was biopsied.Statistical analysis
Comparison of clinical and demographic variables between sur-
gical and RT primary treatment groups was done using two-sample
t-test for age, Fisher’s exact test for sex, clinical T and N classifica-
tions and Pearson’s Chi-squared test with computed p-values by
Monte Carlo simulation (based on 2000 replicates) for smoking
and drinking status and clinical AJCC stage. Toxicities between
the two groups were compared using Fisher’s exact test.
Overall survival (OS) and locoregional recurrence-free survival
(LRFS) were analyzed using the Kaplan–Meier method and log-
rank test for group comparison. Hazard ratios (HR) were estimated
using proportional hazards Cox regression model. We estimated
the crude HR and the adjusted HR controlling for the clinical and
demographic variables with different distribution between treat-
ment groups. LRFS was defined as the time from the first day of
treatment to loco-regional relapse or death from any cause. Cases
of persistent local disease after treatment, defined as presence of
viable tumor cells within 6 months of treatment (surgery or defini-
tive/adjuvant RT), were considered events for LRFS endpoint at the
time of evaluation. OS was defined as time elapsed from the first
day of treatment to death from any cause.Results
Sixty-one patients were initially identified with cT1-T2 cN0-N1
M0 OPSCC. They were treated with surgical resection or primary
RT. Seven were surgically upstaged to pT1 pN2(2), pT2 pN2 (3)
or pT3 pN0 (2). Fifty-two (85%) were male and 9 female (15%), with
a median age of 57 years-old (range 36–86). Forty-nine (80%) were
current moderate to heavy-smokers (more than 10 pack-years) and
37 (61%) were current moderate to heavy-drinkers (more than 14
units of alcohol per week).
The primary site included tonsil in 34 patients (56%), soft palate
in 15 (24%) and base of tongue in 12 (20%). The tumor was clini-
cally classified as T1 in 17 patients (28%) and T2 in 44 (72%).
Forty-two were node-negative (69%) and 19 node-positive (31%).
The disease was in stage I in 13 patients (21%), stage II in 29
(48%) and stage III in 19 (31%). Patient demographics and tumor-
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design algorithm.
Forty-two patients received primary surgery (69%). Thirty-
seven required adjuvant treatment (88%) with RT (24) or CRT
(13), due to positive surgical margins (12), close margins (24)
and/or other features, including lymphovascular invasion (6),
pN2 (5),extracapsular nodal spread (4), perineural invasion (4)
and/or pT3 (2).
Nineteen were treated with primary RT (31%) and 3 of them
received concomitant CT.
Overall, 56 patients (92%) were submitted with primary (19) or
adjuvant RT (37). Thirty-three were treated with IMRT-SIB (71%)
and thirteen (29%) with 3D-CRT.
The median follow-up for the surviving patients was 5.4 years
(range 0.3–7.9 years).
Three patients had tumor persistence (5%), 5 had local failure
(8%) and 2 regional failure (3%). Of these 10 patients, 4 had been
treated with primary RT, 1 with primary surgery and 5 with sur-
gery and adjuvant RT for close margins.
Overall, 3-year and 5-year OS were 73% and 63%, and 3-year and
5-year LRFS were 68% and 54%, respectively. The Kaplan–Meier OS
and DFS curves are shown in Figs. 2 and 3. Median OS was 6.5 years
in the surgery group and was not reached in the RT group or when
considering the whole cohort. Median LRFS was 6.5 years in the
whole cohort, 6.1 years in the surgery group but not reached in
the RT group.
The 3-year and 5-year OS were 77% and 71% in the RT group vs.
71% and 59% in the surgery group, respectively (p = 0.30). The 3-
year and 5-year LRFS were 71% and 64% in the RT group vs. 66%
and 50% in the surgery group, respectively (p = 0.24). The crude
hazard ratios for the comparison of OS and LRFS between primary
RT vs. primary surgery were 0.60 (95% CI 0.22–1.61) and 0.59 (95%
CI 0.24–1.45), respectively. When adjusting for age and location,
the HRs for OS and LRFS both decreased to 0.51 (95% CI 0.17–
1.54) and 0.52 (95% CI 0.19–1.44), respectively, without statistical
significance in both cases.Table 1
Patient demographics and tumor-related characteristics.
All patients (n = 61) Prima
Age, years
Mean (±SD) 59 (±11) 57 (±
Median (IQR) 57 (51–65) 55 (5
Range 36–86 36–8
Sex, n (%)
Male 52 (85) 36 (8
Female 9 (15) 6 (14
Smoking status, n (%)
Current moderate/heavy smoker 49 (80) 34 (8
Former smoker 4 (7) 2 (5)
Lifelong non-smoker 8 (13) 6 (14
Drinking status, n (%)
Current moderate/heavy drinker 37 (61) 24 (5
Former drinker 4 (7) 3 (7)
Lifelong non-drinker 20 (33) 15 (3
Subsite, n(%)
Tonsil 34 (56) 30 (7
Soft palate 15 (24) 7 (17
Base of tongue 12 (20) 5 (12
Clinical T stage, n (%)
T1 17 (28) 12 (2
T2 44 (72) 30 (7
Clinical N stage, n (%)
N0 42 (69) 29 (6
N1 19 (61) 13 (3
Clinical AJCC stage, n (%)
I 13 (21) 9 (21
II 29 (48) 20 (4
III 19 (31) 13 (3
AJCC, American Joint Committee on Cancer; SD, standard deviation; IQR, Interquartile raTwenty-three patients died, 5 due to local progression, and the
remaining due to non-oropharyngeal cancer causes: second tumor
(5), infection (4), suicide (1), undetermined (8). No one developed
distant metastasis.
Acute grade 3 toxicity was reported by 19 patients (34% of the
patients treated with RT). The most common were mucositis
(29%), dysphagia (18%), dermatitis (11%) and xerostomia (2%). They
were just as common in the adjuvant setting as they were in the
primary one (32% vs. 37%; odds ratio [OR] = 1.21; 95% CI 0.32–
4.44; p = 0.77). Most of these patients (17) were treated with IMRT
and half of them (9) received concomitant CRT. The odds of acute
grade 3 toxicity was higher in concomitant CRT compared to iso-
lated RT (56% vs. 25%; OR = 3.75, 95% CI 0.96–15.56; p = 0.03)
and also in IMRT compared to 3D-CRT (43% vs. 13%; OR = 5.04;
95% CI 0.95–51.57; p = 0.059), but the latter was not statistically
significant. There was no grade 4 acute side effects.
Severe late toxicity was reported by 6 patients (11%), all of
whom had grade 4 osteoradionecrosis (ORN) of the jaw (half
required hyperbaric oxygen therapy). There was no grade 3 late
side effects. Three of the patients who had mandibular ORN
received primary RT and the other 3 adjuvant RT. Four were treated
with 3D-CRT and 2 were given concomitant CT. The odds of ORN
was higher in 3D-CRT-treated patients than IMRT (25% vs. 5%; OR
= 6.08, 95% CI 0.76–74.97, p = 0.049). No statistically significant
association could be demonstrated between ORN and primary or
adjuvant RT (16% vs. 8%; OR = 2.09, 95% CI 0.25–17.44, p = 0.40)
or concomitant CRT (13% vs. 10% isolated RT; OR = 1.28, 95% CI
0.10–10.15, p = 1.00).Discussion
The management of OPSCC should be performed by specialized
teams in a multidisciplinary tumor board setting. The choice of the
right treatment is complex and should take into consideration
multiple factors related to the patient (such as performance status,ry surgery (n = 42) Primary radiotherapy (n = 19) p
11) 63 (±10) 0.041
0–63) 63 (55–70)
6 47–80
6) 16 (84) 1.000
) 3 (16)
1) 15 (79) 0.757
2 (10.5)
) 2 (10.5)
7) 13 (68) 0.818
1 (5)
6) 5 (26)
1) 4 (21) 0.002
) 8 (42)
) 7 (37)
9) 5 (26) 1.000
1) 14 (74)
9) 13 (68) 1.000
1) 6 (32)
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stage, HPV status) and the physician’s expertise.
Early-stage OPSCC is currently treated with primary surgery or
primary RT, based on previous retrospectives series that have61 patients with cT
submitted to primar
42 treated with primary surgery
24 with close margins (<5
12 with positive margins 







Fig. 1. Study design algorithm. OPSCC, oropharyngeal squamous
Fig. 2. Estimate of overall survival for patients with cT1-T2 cN0-1 o
Fig. 3. Estimate of locoregional recurrence-free survival for patients with cT1-shown similar control and survival rates [8]. On top of survival,
at the moment, the discussion between the two options is also
about toxicities and quality of life, since the epidemiological shift
toward HPV-related cancer has meant that we are now treating1-T2 cN0-N1 OPSCC
y surgery or primary RT








cell carcinoma. RT, radiotherapy. CRT, chemoradiotherapy.
ropharyngeal squamous cell carcinoma by upfront treatment.
T2 cN0-1 oropharyngeal squamous cell carcinoma by upfront treatment.
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vive and suffer the long-term side-effects. Given the fact that both
modalities are associated with complications [8], focus has turned
to minimally invasive techniques (such as transoral robotic sur-
gery, TORS) or de-escalation strategies (reduction of radiation dose
or sensitizer modification in HPV-positive disease) [10]. However,
until randomized trials clarify the benefit of TORS or reduced-
dose radiation over conventional treatments and because robotic
surgery is not readily available in most hospitals, the discussion
between surgery vs. RT in early-stage OPSCC is still open. To our
knowledge, published studies directly comparing the two modali-
ties, specifically in early-stage disease, are limited and therefore,
that is the purpose of this report.
Before comparing the two groups, it is important to note that
despite the curative intent of surgery, 88% of these patients
received multimodal treatment. In most cases, adjuvant therapy
was required due to close (57%) or positive (29%) margins. There-
fore, surgery as sole treatment was unlike in the majority of
patients, since only 12% (n = 5) did not receive adjuvant therapy.
Nevertheless, when we consider the primary approach, as
expected, there was no significant difference in 3-year and
5-year OS and LRFS between the two treatments. Our 5-year OS
(63%) was slightly lower than average rates reported in literature,
which is usually over 80% [3].
In terms of toxicity, our results are consistent with previous
studies that have shown similar rates of grade 3 acute side-
effects: mucositis in 14–25% of patients, dysphagia in 10–15%
and dermatitis in 6–18% [11–13]. The late toxicity rate was lower
than other series, who report up to 35% severe late side-effects
[14]. Our rate of ORN, however, was higher than the 5–7%
described in the literature [3], but previous reports of our center
have already documented poor oral healthcare among our patients
[15].
The main limitation of this report is the retrospective nature of
this analysis and the small sample size. Another drawback is that
outcomes were not stratified by HPV status (our center did not
routinely test for HPV during the time period analyzed in this
study). Due to its strong prognostic value, this could possibly have
shown some differences between the two treatments. However,
comparing the two groups (surgery and RT), both had 80% of mod-
erate/ heavy smokers and that could override the HPV impact. In
addition, knowing that function and quality of life are currently
main endpoints when comparing both treatments, the absence of
their thorough evaluation also impairs the comparison between
surgery and RT.
Our preliminary results have already been presented [16]. As
our data matured, results consistently show no difference in out-
comes regardless the primary treatment.
To conclude, despite the limitations mentioned above, our
results are consistent with the literature. Until randomized trials
are published, this report contributes to the growing knowledge
and experience in OPSCC, through a direct comparison between
surgery and primary RT in early-stage disease.
Conclusions
This analysis confirms there is not a significant difference in OS
and LRFS between surgery and primary RT. However, it highlightsthe fact that most patients submitted to upfront surgical resection
required adjuvant treatment. RT was associated with significant
acute side effects, both in the adjuvant and the primary setting,
but the overall late toxicity rate was low. Further studies should
help clarify the best first approach for each patient, in order to pre-
vent the need for unnecessary treatments and the risk of toxicity.
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